Market Summary
USD7.48-0.15
Market Closed-1.97%
RXRX Stock Price
RXRX RSI Chart
RXRX Valuation
RXRX Price/Sales (Trailing)
RXRX Profitability
RXRX Fundamentals
RXRX Revenue
RXRX Earnings
Price Action
52 Week Range
4.9214.18
(Low)(High)
Last 7 days
-7.6%
Last 30 days
-6.3%
Last 90 days
-11.7%
Trailing 12 Months
19.7%
RXRX Financial Health
RXRX Investor Care
Financials for RECURSION PHARMACEUTICALS
| Income Statement (Last 12 Months) | (In Thousands) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 38.8% | 39,843 | 28,700 | 18,074 | 12,949 | 10,178 |
| Operating Expenses | - | 192,953 | - | - | - | - |
| S&GA Expenses | 0.8% | 81,599 | 80,962 | 77,164 | 69,819 | 57,682 |
| R&D Expenses | -2.7% | 155,696 | 160,008 | 152,418 | 143,603 | 135,271 |
| Interest Expenses | -3.5% | 55.00 | 57.00 | 168 | 440 | 680 |
| Net Income | 3.0% | -239,476 | -246,917 | -233,900 | -211,741 | -186,479 |
| Net Income Margin | 30.1% | -6.01* | -8.60* | -10.38* | -3.94* | -18.32* |
| Free Cahsflow | 9.7% | -120,583 | -133,478 | -113,428 | -75,195 | -198,412 |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 14.7% | 701 | 612 | 673 | 734 | 610 |
| Current Assets | 18.3% | 570 | 482 | 546 | 619 | 535 |
| Cash Equivalents | 21.0% | 550 | 455 | 454 | 508 | 285 |
| Net PPE | 2.8% | 88.00 | 86.00 | 82.00 | 71.00 | 65.00 |
| Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Liabilities | -3.6% | 215 | 223 | 235 | 241 | 67.00 |
| Current Liabilities | 20.7% | 100 | 83.00 | 97.00 | 86.00 | 47.00 |
| Long Term Debt | - | 1.00 | - | - | - | - |
| Shareholder's Equity | 25.2% | 486 | 388 | 438 | 494 | 543 |
| Retained Earnings | -9.9% | -639 | -582 | -521 | -456 | -400 |
| Additional Paid-In Capital | 16.0% | 1,125 | 970 | 959 | 950 | 943 |
| Shares Outstanding | 9.7% | 191 | 174 | 173 | 171 | 170 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 16.4% | -83.52 | -99.93 | -78.44 | -50.47 | -158 |
| Share Based Compensation | 13.7% | 28.00 | 25.00 | 19.00 | 19.00 | 15.00 |
| Cashflow From Investing | 29.7% | 193 | 149 | -97.87 | -109 | -271 |
| Cashflow From Financing | 1318.0% | 154 | 11.00 | -2.55 | 458 | 459 |
Risks for RXRX
What is the probability of a big loss on RXRX?
96.0%
Probability that RECURSION PHARMACEUTICALS stock will be more than 20% underwater in next one year
96.0%
Probability that RECURSION PHARMACEUTICALS stock will be more than 30% underwater in next one year.
83.2%
Probability that RECURSION PHARMACEUTICALS stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does RXRX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if RECURSION PHARMACEUTICALS was unfortunately bought at previous high price.
Drawdowns
Returns for RXRX
Cumulative Returns on RXRX
Which funds bought or sold RXRX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | BAILLIE GIFFORD & CO | added | 14.94 | -38,398,200 | 191,369,000 | 0.20% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 9.41 | -26,251 | 101,749 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -67.51 | -59,000 | 18,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -154,415 | 405,585 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 6.08 | -405,000 | 1,345,000 | 0.01% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -52,000 | - | -% |
2023-02-15 | MetLife Investment Management, LLC | unchanged | - | -211,639 | 556,361 | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | reduced | -87.93 | -31,433,400 | 3,011,560 | -% |
2023-02-15 | JANE STREET GROUP, LLC | reduced | -21.52 | -158,113 | 208,887 | -% |
2023-02-15 | Metropolitan Life Insurance Co/NY | unchanged | - | -24,429 | 64,571 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
RECURSION PHARMACEUTICALS News
Schedule 13G FIlings of RECURSION PHARMACEUTICALS
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | lux capital management, llc | 3.3% | 6,004,722 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 5.54% | 10,057,363 | SC 13G | |
| Feb 03, 2023 | blackrock inc. | 5.9% | 10,667,624 | SC 13G | |
| Jan 24, 2023 | baillie gifford & co | 13.66% | 24,820,850 | SC 13G/A | |
| Oct 31, 2022 | mubadala investment co pjsc | 6.3% | 11,291,937 | SC 13D/A | |
| Feb 14, 2022 | data collective iv, l.p. | 3.7% | 5,941,120 | SC 13G | |
| Feb 14, 2022 | lux capital management, llc | 8.2% | 13,021,519 | SC 13G |
RXRX Fair Value
RECURSION PHARMACEUTICALS fair value in different scenarios
The table shows the Fair Value estimates for RECURSION PHARMACEUTICALS for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 0.65 -91.31% | 0.69 -90.78% | 0.86 -88.50% | 1.13 -84.89% | 1.67 -77.67% |
| Current Inflation | 0.64 -91.44% | 0.68 -90.91% | 0.83 -88.90% | 1.06 -85.83% | 1.53 -79.55% |
| Very High Inflation | 0.64 -91.44% | 0.67 -91.04% | 0.80 -89.30% | 0.99 -86.76% | 1.36 -81.82% |
Historical RECURSION PHARMACEUTICALS Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of RECURSION PHARMACEUTICALS
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 15, 2023 | 4 | Insider Trading | |
| Mar 10, 2023 | 4 | Insider Trading | |
| Mar 10, 2023 | 8-K | Current Report | |
| Mar 09, 2023 | 4 | Insider Trading | |
| Mar 06, 2023 | 4 | Insider Trading | |
| Mar 03, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 01, 2023 | 4 | Insider Trading | |
| Feb 28, 2023 | 4 | Insider Trading | |
| Feb 27, 2023 | 10-K | Annual Report |
Latest Insider Trading transactions for RXRX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-09 | Gibson Christopher | sold | -116,620 | 7.7747 | -15,000 | chief executive officer |
2023-03-08 | Gibson Christopher | sold | -8,086 | 8.0867 | -1,000 | chief executive officer |
2023-03-08 | Gibson Christopher | sold | -573,925 | 8.096 | -70,890 | chief executive officer |
2023-03-08 | Gibson Christopher | sold | -32,361 | 8.0904 | -4,000 | chief executive officer |
2023-03-08 | Gibson Christopher | acquired | - | - | 20,000 | chief executive officer |
2023-03-08 | Gibson Christopher | sold | -161,900 | 8.095 | -20,000 | chief executive officer |
2023-03-08 | Gibson Christopher | acquired | - | - | 4,000 | chief executive officer |
2023-03-08 | Gibson Christopher | acquired | 232,500 | 2.48 | 93,750 | chief executive officer |
2023-03-08 | Gibson Christopher | acquired | - | - | 1,000 | chief executive officer |
2023-03-08 | Gibson Christopher | gifted | - | - | -10,000 | chief executive officer |
Chistopher C. Gibson
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Income Statement
2022-12-31Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenue | |||
| Revenue | $ 39,843 | $ 10,178 | $ 3,962 |
| Operating costs and expenses | |||
| Cost of revenue | 48,275 | 0 | 0 |
| Research and development | 155,696 | 135,271 | 63,319 |
| General and administrative | 81,599 | 57,682 | 25,258 |
| Total operating costs and expenses | 285,570 | 192,953 | 88,577 |
| Loss from operations | (245,727) | (182,775) | (84,615) |
| Other income (loss), net | 6,251 | (3,704) | (2,391) |
| Net loss | $ (239,476) | $ (186,479) | $ (87,006) |
| Per share data | |||
| Net loss per share of Class A and B common stock, basic (in dollars per share) | $ (1.36) | $ (1.49) | $ (3.99) |
| Net loss per share of Class A and B common stock, diluted (in dollars per share) | $ (1.36) | $ (1.49) | $ (3.99) |
| Weighted-average shares (Class A and B) outstanding, basic (in shares) | 175,537,487 | 125,348,110 | 21,781,386 |
| Weighted-average shares (Class A and B) outstanding, diluted (in shares) | 175,537,487 | 125,348,110 | 21,781,386 |
| Operating revenue | |||
| Revenue | |||
| Revenue | $ 39,681 | $ 10,000 | $ 3,413 |
| Grant revenue | |||
| Revenue | |||
| Revenue | $ 162 | $ 178 | $ 549 |
RXRX Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 549,912 | $ 285,116 |
| Restricted cash | 1,280 | 1,552 |
| Accounts receivable | 0 | 34 |
| Other receivables | 2,753 | 9,056 |
| Investments | 0 | 231,446 |
| Other current assets | 15,869 | 7,514 |
| Total current assets | 569,814 | 534,718 |
| Restricted cash, non-current | 7,920 | 8,681 |
| Property and equipment, net | 88,192 | 64,725 |
| Operating lease right-of-use assets | 33,255 | 0 |
| Intangible assets, net | 1,306 | 1,385 |
| Goodwill | 801 | 801 |
| Other non-current assets | 0 | 35 |
| Total assets | 701,288 | 610,345 |
| Current liabilities | ||
| Accounts payable | 4,586 | 2,819 |
| Accrued expenses and other liabilities | 32,904 | 32,333 |
| Unearned revenue | 56,726 | 10,000 |
| Notes payable | 97 | 90 |
| Operating lease liabilities | 5,952 | 0 |
| Lease incentive obligation | 0 | 1,416 |
| Total current liabilities | 100,265 | 46,658 |
| Deferred rent | 0 | 4,110 |
| Unearned revenue, non-current | 70,261 | 6,667 |
| Notes payable, non-current | 536 | 633 |
| Operating lease liabilities, non-current | 44,420 | 0 |
| Lease incentive obligation, non-current | 0 | 9,339 |
| Total liabilities | 215,482 | 67,407 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of December 31, 2022 and December 31, 2021, respectively; 191,022,864 shares (Class A 183,209,655 and Class B 7,813,209) and 170,272,462 (Class A 160,906,245 and Class B 9,366,217) issued and outstanding as of December 31, 2022 and December 31, 2021, respectively | 2 | 2 |
| Additional paid-in capital | 1,125,360 | 943,142 |
| Accumulated deficit | (639,556) | (400,080) |
| Accumulated other comprehensive loss | 0 | (126) |
| Total stockholders’ equity | 485,806 | 542,938 |
| Total liabilities and stockholders’ equity | $ 701,288 | $ 610,345 |